These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1963579)

  • 21. Chemotherapy in the treatment of cancer of the ovary.
    Smith JP; Rutledge F
    Am J Obstet Gynecol; 1970 Jul; 107(5):691-703. PubMed ID: 4316665
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum alpha-1 proteinase inhibitor in advanced cancer: mass variants and functionally inert forms.
    Chawla RK; Lawson DH; Sarma PR; Nixon DW; Travis J
    Cancer Res; 1987 Feb; 47(4):1179-84. PubMed ID: 3492270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haptoglobin and proteinase inhibitors in the blood serum of women with inflammatory, benign and neoplastic lesions of the ovary.
    Warwas M; Gerber J; Pietkiewicz A
    Neoplasma; 1986; 33(1):79-84. PubMed ID: 2421174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.
    Carbotti G; Orengo AM; Mezzanzanica D; Bagnoli M; Brizzolara A; Emionite L; Puppo A; Centurioni MG; Bruzzone M; Marroni P; Rossello A; Canevari S; Ferrini S; Fabbi M
    Int J Cancer; 2013 Jun; 132(11):2597-605. PubMed ID: 23169448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Maintenance chemotherapy for ovarian adenocarcinoma with carboquone: doses and side effects (author's transl)].
    Sekiya S; Iwasawa H; Takamizawa H
    Nihon Sanka Fujinka Gakkai Zasshi; 1982 May; 34(5):634-6. PubMed ID: 6282997
    [No Abstract]   [Full Text] [Related]  

  • 26. Relation between raised concentrations of fucose, sialic acid, and acute phase proteins in serum from patients with cancer: choosing suitable serum glycoprotein markers.
    Turner GA; Skillen AW; Buamah P; Guthrie D; Welsh J; Harrison J; Kowalski A
    J Clin Pathol; 1985 May; 38(5):588-92. PubMed ID: 2582003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [T-activin in the combined therapy of patients with benign ovarian tumors].
    Griaznova IM; Makarov OV; Arion VIa; Epeĭkina TN
    Akush Ginekol (Mosk); 1987 Jul; (7):28-31. PubMed ID: 2825557
    [No Abstract]   [Full Text] [Related]  

  • 28. [Low-grade serous, mucinous carcinoma].
    Nakayama K; Kyo S
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):179-82. PubMed ID: 25834916
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical usefulness of serum sialyl SSEA-1 antigen levels in patients with epithelial ovarian cancer. Comparative effectiveness of sialyl SSEA-1 and CA 125.
    Kobayashi H; Kawashima Y
    Gynecol Obstet Invest; 1990; 30(1):52-8. PubMed ID: 1977666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total inhibin is a potential serum marker for epithelial ovarian cancer.
    Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunochemical studies on blood groups LXII. Fractionation of hog and human A, H, and AH blood group active substance on insoluble immunoadsorbents of Dolichos and Lotus lectins.
    Pereira ME; Kabat EA
    J Exp Med; 1976 Feb; 143(2):422-36. PubMed ID: 55452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prediction of the clinical response of ovarian cancer to chemotherapy using an in vitro anticancer drug sensitivity test].
    Li ZX
    Zhonghua Fu Chan Ke Za Zhi; 1988 Sep; 23(5):287-9, 318. PubMed ID: 3250811
    [No Abstract]   [Full Text] [Related]  

  • 33. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of ovarian carcinoma. Current concepts and future prospects.
    Tobias JS; Griffiths CT
    N Engl J Med; 1976 Apr; 294(16):877-82. PubMed ID: 175277
    [No Abstract]   [Full Text] [Related]  

  • 35. The hypercoagulable state and pulmonary embolism in patients with ovarian carcinoma.
    Planner RS; O'Sullivan EF; Campbell JJ; Ball DL
    Aust N Z J Obstet Gynaecol; 1978 Aug; 18(3):209-12. PubMed ID: 217329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
    Tarumi Y; Mori T; Matsushima H; Kokabu T; Tsuchiya H; Kitawaki J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):347-351. PubMed ID: 29121427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy in advanced ovarian cancer.
    Schein PS
    Geriatrics; 1973 Dec; 28(12):89-95. PubMed ID: 4128004
    [No Abstract]   [Full Text] [Related]  

  • 40. Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination.
    Williams CJ; Mead B; Arnold A; Green J; Buchanan R; Whitehouse M
    Cancer; 1982 May; 49(9):1778-83. PubMed ID: 6280845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.